Articles On Immutep (ASX:IMM)

ShareCafeChinese protests over lockdowns continue: Aus shares 0.07% lower at noon by Peter Milios   The global economic outlook is shaky, as growing protests in the world’s largest manufacturing nation are creating a new level of uncertaint...

Sonic has taken a stake in Microba Immutep enters into second deal with Merck (Germany) and Pfizer  ImpediMed has a new CEO   Sonic takes strategic stake in Microba Giant healthcare stock Sonic Healthcare (ASX:SHL) has bought a stake in s...

Immutep (ASX:IMM) has announced a new clinical trial collaboration under which the Australian company's investigative LAG-3 immunotherapy, efti, will be studied with Merck and Pfizer's PBS-listed BAVENCIO (avelumab).

The ASX is set to open slightly higher on Tuesday Wall Street fell almost 2% overnight as protests in China spread Crypto lender BlockFi has filed for bankruptcy The ASX is poised to edge slightly higher on Tuesday despite a 1.5% – 1.75%...

ShareCafeImmutep (ASX: IMM) – A Transformative Year for LAG-3 Therapies Immutep Limited (ASX:IMM) CEO and Executive Director Marc Voigt discusses the LAG-3 landscape, the company’s portfolio of therapies, encouraging data from the 2022 SIT...

ASX health stocks have been out of favour this year with rotation away from growth to value sector Morgan’s Scott Power said a lot of biotechs aren’t able to convert their complex science into layman’s terms Hot money going to lithium and...

ShareCafeEarly gains quickly wiped off: ASX closes the day 0.16% lower by Peter Milios   All sectors except Materials and Energy are lower in today’s day of trading, as the ASX finishes 0.16 per cent or 11.70 points lower at 7146.30. Materi...

The ASX gave up early gains as last week’s fierce global share rally showed signs of losing momentum.   The S&P/ASX 200 touched a five-month high before fading to a loss of 12 points or 0.16 per cent. The decline came as Asian mar...

ShareCafeMarket losing momentum, materials the saviour: ASX flat at noon by Lauren Hayes   Last week’s gains have not continued with the same momentum this morning. Materials, up 3.4 per cent, is bolstering the local market following a rise...

The share market touched a five-month high before shedding its gains as a decline in US futures undermined a China-fuelled rally in resource stocks. The S&P/ASX 200 rallied to within four points of 7200 for the first time since June....

Immutep (IMM) receives a $986,000 tax refund from the Australian government’s research and development (R&D) tax incentive programThe cash rebate is mostly for money Immutep spent on its clinical study work during its 2021 financial yea...

Highlights Australian shares opened higher on Monday. The ASX 200 gained in the opening trade, rising 25.20 points, or 0.35%, to 7,183.20. On Friday, the benchmark index closed 2.8% higher at 7,158 points. Australian s...

Imugene (IMU) presents new data for its onCARlytics oncolytic virus at the Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in Boston, USThe company presented two different sets — the first for a treatment with fellow biotec...

Immutep (IMM) receives two new patents from the Japanese Patent Office and South Korean Patent Office for its immunotherapy treatment for cancerThe new patent protects Immutep’s intellectual property relating to combined therapeutic prepara...

ShareCafeA sea of red in today’s trading: ASX closes 1.84% lower by Peter Milios   All but one sector finished lower today, as the ASX reacted to the overnight news that the Fed has increased rates by 75 basis points. Materials, Consumer Di...

ShareCafeAll red across the board following US rate hike sentiment: ASX down 1.96% at noon By Lauren Hayes   US equities plunged after Fed Chair Jerome Powell indicated policymakers would continue raising interest rates to fight persistent...

The All Ordinaries Index (ASX: XAO) may be sinking today but that hasn’t stopped a couple of ASX healthcare shares from racing higher. Here’s why these two All Ords shares are smashing the index on Thursday: Immutep Ltd (ASX: IMM) The...

HitIQ signs deal with Western Australian Football Commission Rhthym Bio expands into NZ Immutep’s Phase II TACTI-002 trial has been accepted for an oral presentation HitIQ signs with WAFC Concussion tech specialist HitIQ (ASX:HIQ) rose 40...

The ASX is set to plunge on Thursday after a crash in New York US Fed unleashed another jumbo 75bp rate hike Fed boss Jerome Powell spooked the markets during his speech   The ASX is poised to plunge on Wednesday, tracking movements in Ne...

ShareCafeASX increases slightly ahead of today’s rate rise: Aus shares 0.3% higher at noon by Peter Milios   Last week’s rally for US equities ground to a halt overnight ahead of this week’s Federal Reserve decision on interest rates, as te...

Immutep (IMM) is given approval by the Independent Data Monitoring Committee (IDMC) to carry on with its planned phase IIb TACTI-003 trialThe IDMC reviewed the initial safety data and concluded that the trial should continue with no modific...

ShareCafeMarket unfazed by CPI data: ASX finishes 0.18% higher by Peter Milios   CPI data from the September quarter has sharply exceeded estimates. As such, multiple banks have made predictions for the next rate rise. Commonwealth Bank (AS...

ShareCafeAustralian headline inflation hits highest in 32 years: ASX up 0.12% at noon by Lauren Hayes   The S&P/ASX 200 posted gains this morning as sentiment from Wall Street overnight improved over the Fed potentially turning less agg...

Neurotech says its NTI164 drug for paediatric autism showed improvements in symptoms Arovella closing Perth R&D facility to focus on invariant Natural Killer T (iNKT) cell platform Argenica reports safety and efficiacy of stroke drug A...

ShareCafeEnergy and Materials only sectors left lagging: ASX closes 0.28% higher by Peter Milios   In today’s events, independent commission agency ASIC has launched legal action against BPS Financial, the company behind Gold Coast-based di...

ShareCafeOptimism out of the US boosts sentiment: ASX up 0.6% at noon by Lauren Hayes   Positive gains in the local market have extended into a second day as optimism out of the US about corporate earnings ahead of several key tech reports...

We take a look at how the 15 biotech IPOs that listed in 2021 are faring now Only two IPO stocks from 2021 have gained since listing We also look at the best and worst performing ASX stocks over the past month   There were 191 ASX IPOs in...

ShareCafeImmutep (ASX: IMM) Receives Fast Track Designation from FDA   Immutep Limited (ASX: IMM) CEO and Executive Director Marc Voigt discusses the FDA fast track designation received in first-line non-small cell lung cancer, the company...

Emerging gold miner Tietto Minerals has a new Chinese Mining giant as a substantial shareholder Environment play LGI has new substantial shareholders since listing on the ASX last week Lunnon Metals loses substantial shareholders while Bas...

During latest period of volatility many health stocks have seen their share prices remain quite stable Several ASX health stocks have rallied this week on positive news including Polynovo on $5 million sales month Telix Pharmaceuticals ral...

ShareCafeEnergy’s advancements just enough to lift the ASX: Aus shares close 2.2% higher by Peter Milios   The ASX’s two-day positive run has turned to three days. It finished the day having increased slightly by 0.03 per cent or 1.80 point...

Australian immunotherapy company Immutep has secured fast-track designation from the US FDA for its eftilagimod alpha for use in combination with MSD's KEYTRUDA (pembrolizumab).

Blood clot programs have taken the spotlight recently as new discoveries made Two ASX health stocks are in the blood clot space Top performing ASX healthcare stocks in the past month Blood clots were top of biotech news this week after re...

Immutep (IMM) receives US FDA Fast Track designation for its efti drug candidate as a treatment for non-small cell lung cancer (NSCLC)The designation — Immutep’s second for the drug — is specifically for efti when used in combination with c...

Paradigm successfully meets primary endpoint of Phase 2 trial Immutep granted Fast Track designation by the FDA ImpediMed signs strategic partnership with GenesisCare Paradigm Biopharma (ASX:PAR) surged 19% this morning after announcing t...

The Imugene Limited (ASX: IMU) share price had a rough month despite multiple clinical trial updates. Imugene shares have fallen 30.77% from 26 cents at market close on 31 August to 18 cents at market close on 30 September....

Immutep (IMM) receives a $2.7 million research and development tax incentive from the French GovernmentThe company received the funds under France’s research tax credit scheme, which sees eligible French companies reimbursed for 30 per cent...

Immutep has provided a clinical development update for its first-in-class LAG-3 antigen-presenting cell, activator product candidate, eftilagimod alpha, and announced a major appointment to its board.

Immutep (IMM) signs a material transfer agreement with the Maria Skłodowska-Curie National Research Institute of Oncology in Warsaw, PolandThe partnership will enable an investigator-initiated open label Phase II clinical trial to evaluate...

Uscom’s device is included in China’s emergency guidelines Poland provides grant for Immutep’s Phase 2 trial Medical device company Uscom (ASX:UCM) said that it has been included in the national emergency medicine guidelines for acute hea...

ShareCafeEvening Report: 30 August, 2022 by Paul Sanger   Australian shares have clawed back some of yesterday’s heavy losses despite another slump in global markets over the possibility of more aggressive US and European interest rate hike...

Immutep (IMM) receives a new patent for its immunotherapy treatment for cancer from the Japanese Patent Office The new patent protects Immutep’s intellectual property relating to combined therapeutic preparations, comprising its lead acti...

ShareCafeLunch Report: 30 August, 2022 by Paul Sanger   The ASX had a solid start to the trading session Tuesday, recovering some of yesterday’s material fall. At noon, the S&P/ASX 200 is 0.48 per cent or 33.50 points higher at 6999.00....

ShareCafeStocks of the Hour: 30 August, 2022                    Cobre (ASX:CBE) continues to kick goals, today they announced that their fifth step out drill hole of the ongoing diamond drill programme at the Ngami Copper Project in t...

30 Aug 2022 - A snapshot of the stocks on the move featuring Cobre (ASX:CBE), Immutep (ASX:IMM) and AD1 Holdings (ASX:AD1).

It is the last day of the busiest week in the August earnings season. Thankfully, you can ease into the weekend with far fewer ASX shares set to report their results today. However, there are still a handful of big names that you might wa...

Immutep (ASX:IMM) has announced new interim data from lung cancer patients in one of its key clinical trials. The phase 2 TACTI-002 trial is studying the company's LAG-3 Candidate, eftilagimod...

Immutep Ltd (ASX: IMM) shares underperformed in FY22 as markets took a turn for the worse. Most of the previous year’s gains were erased. However, the biotech company has caught a bid in July, as healthcare shares continue to strengthen i...

US FDA approves the first clinical trial using naturally derived psychedelic drugs It could open possibilities for other clinical trials to follow suit Best and worst biotechs over the past month In a ground-breaking development, the US F...

ASX biotech shares incurred heavy losses in FY22 as investors piled out of risk assets and moved into higher-quality corners of the market. Here’s a closer look at three noteworthy ASX biotech shares and their outlook for FY23. CSL Ltd...